Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies

BACKGROUND/OBJECTIVE: FKB327 is a biosimilar of the antitumour necrosis factor adalimumab reference product (RP). A randomised, double-blind (DB) phase 3 study compared the efficacy of FKB327 with the RP in patients with active rheumatoid arthritis (RA) inadequately controlled with methotrexate (MTX...

Descripción completa

Detalles Bibliográficos
Autores principales: Genovese, Mark C, Kellner, Herbert, Arai, Yasumasa, Muniz, Rafael, Alten, Rieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299509/
https://www.ncbi.nlm.nih.gov/pubmed/32371430
http://dx.doi.org/10.1136/rmdopen-2019-000987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7299509/
https://www.ncbi.nlm.nih.gov/pubmed/32371430
http://dx.doi.org/10.1136/rmdopen-2019-000987

Ejemplares similares